Royalty Pharma (RPRX) Assets Average (2020 - 2026)
Royalty Pharma (RPRX) posted Assets Average of $19.7 billion for Q1 2026, up 1.2% sequentially from $19.5 billion in Q4 2025, and up 10.06% YoY from $17.9 billion in Q1 2025.
Royalty Pharma (RPRX) Assets Average (2020 - 2026) Analysis & Trends
Royalty Pharma has reported Assets Average for 7 years, with the latest figure at $19.7 billion in Q1 2026.
- Quarterly Assets Average rose 10.06% year-over-year to $19.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.7 billion (up 10.06% YoY) and the FY2025 annual result came in at $18.9 billion, up 9.36% from the prior year.
- Assets Average advanced to $19.7 billion in Q1 2026 per RPRX's latest filing, from $19.5 billion in the prior quarter.
- Over five years, Assets Average peaked at $19.7 billion in Q1 2026 and troughed at $16.1 billion in Q4 2023.
- A 5-year average of $17.6 billion and a median of $17.6 billion in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2024: Assets Average dropped 6.88% in 2023, then rose 12.49% in 2024.
- Over 5 years, Assets Average stood at $17.2 billion in 2022, then slipped by 6.52% to $16.1 billion in 2023, then rose by 12.49% to $18.1 billion in 2024, then climbed by 7.45% to $19.5 billion in 2025, then increased by 1.2% to $19.7 billion in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $19.7 billion, $19.5 billion, and $18.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.82 Bn |
| Mar 31, 2026 | 19.72 Bn |
| Dec 31, 2025 | 19.48 Bn |
| Sep 30, 2025 | 18.84 Bn |
| Jun 30, 2025 | 17.97 Bn |
| Mar 31, 2025 | 17.92 Bn |
| Dec 31, 2024 | 18.13 Bn |
| Sep 30, 2024 | 17.85 Bn |
| Jun 30, 2024 | 16.89 Bn |
| Mar 31, 2024 | 16.26 Bn |
| Dec 31, 2023 | 16.12 Bn |
| Sep 30, 2023 | 16.49 Bn |
| Jun 30, 2023 | 17.10 Bn |
| Mar 31, 2023 | 16.94 Bn |
| Dec 31, 2022 | 17.24 Bn |
| Sep 30, 2022 | 17.71 Bn |
| Jun 30, 2022 | 17.56 Bn |
| Mar 31, 2022 | 17.45 Bn |
| Dec 31, 2021 | 17.62 Bn |
| Sep 30, 2021 | 17.12 Bn |